XML 56 R39.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Summary of Revenue Significant Expenses and Net Loss for Segment

The following table presents revenue, significant expenses and net loss for the Company's segment (in thousands):

 

 

 

Year Ended
December 31,

 

 

 

2024

 

 

2023

 

Collaboration revenue

 

$

1,534

 

 

$

1,558

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

Clinical related costs

 

 

15,156

 

 

 

20,682

 

Employee related costs

 

 

22,828

 

 

 

27,124

 

Product development and manufacturing costs

 

 

3,304

 

 

 

4,326

 

Facilities, support costs and depreciation

 

 

13,579

 

 

 

7,425

 

Professional, consulting and public company costs

 

 

7,400

 

 

 

7,663

 

Legal settlement

 

 

 

 

 

(568

)

Financing costs

 

 

 

 

 

434

 

Impairment of property and equipment

 

 

1,883

 

 

 

1,592

 

Impairment of right-of-use assets

 

 

22,836

 

 

 

 

Restructuring and other related charges

 

 

10,896

 

 

 

 

Total operating expenses

 

 

97,882

 

 

 

68,678

 

Loss from operations

 

 

(96,348

)

 

 

(67,120

)

Other income:

 

 

 

 

 

 

Interest income

 

 

2,952

 

 

 

4,499

 

Total other income

 

 

2,952

 

 

 

4,499

 

Loss before income tax expense

 

 

(93,396

)

 

 

(62,621

)

Income tax expense

 

 

(39

)

 

 

(59

)

Net loss

 

$

(93,435

)

 

$

(62,680

)